I agree. Part of why I believe the announcements of each new trial, or cohort of patients does not have the effect on SP that many believe should.The product has proof of concept, and initial clinical success of considerable clinical significance. More study results dont add anything new - just more of the same (as good as it is).
It will take time and money to complete the current trial (10 + 15 participants, hopefully by years end) and even more for the next one (talking 1000 participants) but the commercialization of the product is where things will potentially change (which is only a few short years ago) and SP rises based on the economics of it rather than hype regarding trial results occur. Been part of this adventure for 10 years....id like to think we are close to the pointy end.
AVR Price at posting:
$19.40 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)